T riple negative breast cancer (TNBC) is negative for the expression of oestrogen and progesterone receptors, and absent of human epidermal growth factor receptor 2 (HER2) overexpression 1-3 . These receptors are molecular targets for treating breast cancer 1-3 . As a result, other than olaparib, a poly(ADP-ribose) polymerase inhibitor that can benefit a small subset of TNBC patients with the BRCA mutation, no approved targeted therapies are available for most TNBC patients. Standard chemotherapy is the only approved option, but it is ineffective, with undesired side effects 4,5 . Therefore, new targeted therapies are critically needed for TNBC.
is almost always deleted together with TP53 in tNBCs. a,b, Genomic alterations of TP53 (hemizygous deletion, homozygous deletion and point mutation) in The Cancer Genome Atlas primary (a) and metastatic (b) breast cancer data set determined by cBioportal (n = 2,051 and 213 biologically independent samples for primary and metastatic cancer, respectively). c, The frequency of hemizygous TP53 loss in five major human breast cancer subtypes (n indicates the number of biologically independent samples for each subtype). HER2, human epidermal growth factor receptor 2. d, Heatmap of genomic segment copy number abnormalities (log-ratio measurements) of human chromosome 17 in TNBCs as well as all the other invasive non-TNBC breast carcinomas. Positive log ratios indicate the degree of copy number gain (red) whereas negative values present the loss (blue). e, Schematic diagram showing genes adjacent to TP53 in the human genome. f, Concomitant deletion of POLR2A in TNBC containing hemizygous loss of TP53. g, Correlation between gene expression and copy number variation for POLR2A and TP53 genes in breast tumours (n indicates the number of biologically independent samples). The box and whisker plots present a five-number summary: minima, lower quartile, centre, upper quartile and maxima. Error bars denote mean ± s.d., and statistical significance was assessed by Student's t-test (unpaired and two-tailed). h, The frequency of TNBC patients with hemizygous TP53 deletion at stages I, II and III. i, Protein levels of POLR2A and p53 in seven different human TNBC cell lines (the experiments were repeated three times independently). j,k, Quantification of POLR2A expression in human breast normal, POLR2A neutral and POLR2A loss TNBC tumour tissue samples (j) and representative images (k). In k, two representative samples are shown for each of the three tissues and the experiments were repeated three times independently. Error bars denote mean ± s.d., and statistical significance was assessed by Student's t-test (unpaired, two-tailed). **P < 0.01, ***P < 0.001. Scale bars, 100 µm. METABRIC and France indicate the origin of the data in The Cancer Genome Atlas (http://atlasgeneticsoncology.org/ tcga_projects.html).
the most frequent in primary human breast cancers, with only 36% (741 out of 2,051) and 0.2% (5 out of 2,051) of cases for mutation and homozygous deletion, respectively (Fig. 1a ). On the contrary, hemizygous deletion of TP53 is highly frequent in both primary and metastatic breast cancers (52% and 55%, respectively, Fig. 1a,b ). In particular, 53% (202 out of 380) of TNBC cases carry the hemizygous deletion of TP53 (Fig. 1c ). Our analyses of the breast cancer genomes show that the TP53 deletion is within a large fragment deletion of Chr17p spanning over ~19.8 megabases of DNA in TNBC and other human breast cancers ( Fig. 1d,e ). The POLR2A and TP53 genes are nearly always co-deleted in the Chr17p deletion region ( Fig. 1f ). Importantly, the POLR2A expression levels are significantly correlated with the copy numbers of POLR2A in the TNBC subtype while this correlation is not significant for p53 ( Fig. 1g and and characterization of nanoparticles for stabilizing POLR2A targeting sirNA. a, Schematic illustration of the core-shell structured nanoparticle synthesized using the double-emulsion approach of water-in-oil-in-water (w/o/w). The aqueous phase containing POLR2A targeting siRNA (siPol2) and chitosan-guanidinate-CO 2 (CG-CO 2 ) is encapsulated in the core of the nanoparticle. Poly(lactic-co-glycolic acid) (PLGA) and dipalmitoylphosphatidylcholine (DPPC) in the organic phase (oil, dichloromethane) were used to form the shell of the nanoparticle. b, Illustrations of the chemical reactions for modification of chitosan with guanidine and for the pH-dependent capture/release of CO 2 with the guanidine-modified chitosan. c, TEM images of the nanoparticles kept under different pH conditions for 3 h at 37 °C. The nanoparticles maintain a spherical morphology and core-shell structure at pH 7.4. At pH 6.0, the nanoparticles become enlarged with a damaged shell (arrows indicated defects on the shell), probably due to the generation of CO 2 inside the nanoparticles. The change is more evident at pH 5.0, with the appearance of an additional peak for the enlarged nanoparticles. Scale bars, 500 nm and 100 nm for low-and high-magnification images (top and bottom rows), respectively. d, Nanoparticle size distribution determined by DLS at pH 7.4, 6.0 and 5.0. e, Electrophoretic gel assay showing the low-pH-responsive release of siPol2 from siPol2@NPs in PBS (RNase free). f, Electrophoretic gel assay showing the stability of free siPol2 compared to siPol2 encapsulated in the nanoparticles (siPol2@NPs) after incubating them in serum at 37 °C for up to 24 h. The observable signal of siPol2@NPs at 24 h indicates that the nanoparticle encapsulation could protect siPol2 from degradation in serum, while the signal of free siPol2 in serum disappeared quickly. The experiments for c-f were repeated three times independently. Supplementary Fig. 1 ). Although one allele deletion of the Chr17p fragment significantly decreases the POLR2A mRNA expression, more severe stages of TNBC are associated with increased frequencies of patients with hemizygous TP53 loss ( Fig. 1h ). This indicates that one copy of POLR2A is sufficient to maintain cell survival. This positive correlation is validated in several TNBC cell lines ( Fig. 1i ).
In immunohistochemical analysis using a tumour tissue microarray containing 100 TNBC samples, the expression of POLR2A was scored according to the staining intensity and proportion of signals in each sample. Accordingly, the copy numbers of POLR2A in the tumour tissue samples were determined by quantitative PCR. A tight correlation was validated between POLR2A copy numbers and protein expression levels ( Fig. 1j,k) . Collectively, these data suggest inhibition of POLR2A is an amenable approach for targeted treatment of TNBC.
Synthesis and characterization of nanoparticles
We developed a core-shell nanoplatform ( Fig. 2a ) for delivering siPol2 to target POLR2A. The core contains siRNA and chitosan modified with guanidine (chitosan-guanidinate (CG), Fig. 2b and Supplementary Fig. 2 ). The guanidine group can react reversibly with CO 2 to form chitosan-guanidinate-CO 2 (CG-CO 2 ) in a pH- (nanoparticles encapsulated with Cy5.5-labelled siPol2 and CG-CO 2 ) and Cy5.5-siPol2@NPs (without CO 2 ) (nanoparticles encapsulated with Cy5.5labelled siPol2 and CG) for 1, 3 and 6 h at 37 °C. The cell nuclei were stained using DAPI (blue), the endo/lysosomes were stained using LysoTracker Green (green), and siPol2 were labelled with Cy5.5 (red). DIC, differential interference contrast. For the Cy5.5-siPol2@NPs (without CO 2 ) group, the green and red fluorescence overlaps at all time points. For the Cy5.5-siPol2@NPs (with CO 2 ) treatment, the overlap is reduced at all three time points and minimal at 6 h. Scale bars, 20 µm and 5 µm for low-and high-magnification images, respectively. The experiments were repeated three times, independently. b, Quantitative analysis of co-localization of Cy5.5-siPol2 with endo/lysosomes labelled with LysoTracker Green. Manders' coefficient M1 denotes the fraction of Cy5.5-siPol2 overlapping with LysoTracker Green, and M2 denotes the fraction of LysoTracker Green overlapping with Cy5.5-siPol2. The coefficients are close to 1 if they are highly co-localized (n = 10 images from three independent experiments). Error bars denote mean ± s.d. *P < 0.05, ***P < 0.001. Statistical significance was assessed by Student t-test (paired, two tailed) and one-way analysis of variance (ANOVA) with a Dunnett's post hoc test for M2 and M1, respectively. . c, Viability of the two types of cells quantified using the cell counting kit (CCK-8) after the aforementioned treatments (n = 3 independent experiments with three replicates in each experiment). d, Protein levels of POLR2A in the two types of cells without or with various treatments. Without any treatment (that is, the two control groups), POLR2A protein expression in POLR2A loss MDA-MB-453 cells is lower than that in POLR2A neutral MDA-MB-231 cells. e, Cell colony assay showing that the POLR2A loss HCC1937 (loss-1 and loss-2) cells have similar proliferation to the parent HCC1937 POLR2A neutral (neutral) cells (n = 3 independent experiments with three replicates in each experiment). f, Cell colony assay with Isogenic POLR2A neutral and POLR2A loss HCC1937 (TP53 +/mut ) cells for confirming the observation that POLR2A loss cells are highly sensitive to POLR2A inhibition using siPol2@NPs. A CRISPR-Cas9 system was used to generate the isogenic HCC1937 cell lines with hemizygous loss of POLR2A. siPol2@NPs could significantly inhibit the proliferation of POLR2A loss HCC1937 (loss-1 and loss-2) cells, but not of parent POLR2A neutral HCC1937 cells (n = 3 independent experiments with three replicates in each experiment). g, Protein levels of POLR2A in isogenic POLR2A loss (loss-1, loss-2) and POLR2A neutral (neutral) HCC1937 cells without (control) and with various treatments, showing the dose-dependent inhibition of POLR2A with the siPol2@NPs. Error bars denote mean ± s.e.m. The experiments in d and g were repeated three times independently.
dependent manner 42 , which is utilized to capture/store CO 2 at neutral pH for release at reduced pH such as that (~pH 5) inside endo/ lysosomes ( Fig. 2b ).
Typical transmission electron microscopy (TEM) images of the siPol2-laden nanoparticles (siPol2@NPs) are shown in Fig. 2c . The siPol2@NPs have a spherical morphology and core-shell struc- ture. The nanoparticles are stable at neutral pH and 110 ± 5.7 nm in diameter with a narrow size distribution ( Fig. 2c,d ) and negatively charged surface (surface zeta potential of −22.4 ± 2.1 mV, Supplementary Fig. 3 ). The size of the nanoparticles synthesized using CG without CO 2 is not significantly affected by either pH 6.0 or pH 5.0 ( Supplementary Fig. 4 ). In contrast, when CG-CO 2 is used, their size changes to 138 ± 25.2 nm and defects (white arrows, Fig. 2c ) show up on some of the nanoparticles at pH 6.0.
When the pH is further reduced to 5.0, the size increases by more than four times to 463 ± 54.8 nm for most nanoparticles (resulting in an additional peak, Fig. 2d ) and defects show up on all nanoparticles ( Fig. 2c) . These results indicate that the CO 2 generation from CG-CO 2 which might contribute to the additional peak at ~450 nm shown in Fig. 2d . The migration of siPol2 into electrophoretic agarose gel is almost completely inhibited by nanoparticle encapsulation with negligible release at pH 7.4 ( Fig. 2e) . Moreover, the strong signal observed at pH 5.0 closely resembles the free siPol2 band. Under pH 6.0, smaller bands, indicating slower release of the siRNA, can be seen. These data demonstrate that the low-pH-activated nanobomb effect of the nanoparticles could trigger release of the encapsulated siPol2. Furthermore, the siPol2@NPs were observable for at least 24 h in serum, whereas most of the free siPol2 degraded within 10 min and no siPol2 was discernible after 3 h in serum ( Fig. 2f and Supplementary Fig. 5 ). These data indicate that the nanoparticles could enhance the stability of the siPol2 in blood and allow for pHtriggered release of the siRNA.
To examine cellular uptake and intracellular trafficking, siPol2 was labelled with a red fluorescence probe (Cy5.5) and encapsulated in the nanoparticles. In MDA-MB-453 TNBC cells treated using nanoparticles without CO 2 , the red fluorescence of Cy5.5 overlaps with the green fluorescence of LysoTracker Green, which stains the endo/lysosomes at all time points ( Fig. 3a, left panel) . In stark contrast, the overlap between the green and red fluorescence is reduced in cells treated using nanoparticles with CO 2 at all three time points (particularly at 6 h) ( Fig. 3a, right panel) , indicating successful escape of the Cy5.5-siPol2 from endo/lysosomes. These observations are confirmed by quantitative analyses of co-localization of Cy5.5-siPol2 with endo/lysosomes in the confocal fluorescence images using Manders' coefficients M1 and M2 43 . As shown in Fig.  3b , M1 is close to 1 at all three time points for the condition without CO 2 , indicating the siRNA encapsulated in the nanoparticles without CO 2 was taken up via endocytosis and stayed in endo/lysosomes. In contrast, M1 is much less than 1 at all three time points (particularly 6 h) for the condition with CO 2 , indicating that CO 2 generation in the nanoparticles can result in effective endo/lysosomal escape of the encapsulated siRNA. The M2 data show that nearly all of the endo/lysosomes contained Cy5.5-siPol2 at 3 and 6 h in the absence of CO 2 generation. For the condition with CO 2 generation, the M2 increases first and then decreases. This is because the uptake of Cy5.5-siPol2 was faster than its endo/lysosomal escape in the first 3 h, and after that the rate of endo/lysosomal escape of Cy5.5-siPol2 surpasses its uptake. Collectively, these data suggest that the low-pH-triggered nano-bomb effect of the nanoparticles facilitates endo/lysosomal escape for cytosolic delivery of siRNAs.
Suppression of PoLr2A inhibits POLR2A loss cancer cell growth
The POLR2A targeted strategy inspired by the data shown in Fig. 1 for killing TNBC cells is illustrated in Fig. 4a . To investigate the sensitivity of POLR2A loss TNBC cells to POLR2A inhibition, MDA-MB-453 (TP53 −/mut , POLR2A −/+ or POLR2A loss ) and MDA-MB-231 (TP53 +/mut , POLR2A +/+ or POLR2A neutral ) breast cancer cells were treated with siPol2@NPs together with control conditions. As shown in Fig. 4b for the colony formation assay, siNT@ NPs (nanoparticles with non-targeting siRNA) are not harmful to MDA-MB-453 cells, which is expected as the nanoparticle formulation contains FDA-approved biocompatible materials. This also indicates that the nano-bomb effect of the nanoparticles alone is not harmful to cells. The free siPol2 did not show any cell killing effect either due to its instability in serum and poor uptake by cells. In contrast, the siPol2@NPs could kill the MDA-MB-453 cells (POLR2A loss ) in a concentration-dependent manner although their toxicity to MDA-MB-231 cells (POLR2A neutral ) is negligible. These observations were confirmed by a cell counting kit-8 (CCK-8) assay (Fig. 4c) . These results indicate the POLR2A loss MDA-MB-453 cells are more sensitive to siPol2@NPs than POLR2A neutral MDA-MB-231 cells, presumably because the partial loss of POLR2A renders MDA-MB-453 cells highly vulnerable to POLR2A inhibition. This is confirmed by the POLR2A protein level in the two cells after treatments (Fig. 4d ). The siPol2@NPs could effectively minimize POLR2A expression in POLR2A loss cells at a siPol2 concentration of 1.0 μg ml −1 . POLR2A expression in POLR2A neutral cells treated with the 1.0 μg ml −1 encapsulated siPol2 is still evident, albeit decreased. Therefore, significant inhibition of POLR2A expression is selectively lethal to POLR2A loss TNBC cells.
To exclude potential genetic differences across cell lines, we also generated two isogenic HCC1937 cell lines with hemizygous loss of POLR2A using CRISPR (clustered regularly interspaced short palindromic repeat)-Cas9 ( Supplementary Fig. 6a,b) . The wildtype HCC1937 is TP53 +/mut , POLR2A +/+ (POLR2A neutral ). The parent and two isogenic POLR2A loss HCC1937 cells exhibited similar cell growth rates (Fig. 4e) , confirming that hemizygous deletion of POLR2A does not affect cell survival. However, hemizygous loss of POLR2A (HCC1937 loss-1 and HCC1937 loss-2 ) markedly sensitizes the HCC1937 cells to siPol2@NPs (Fig. 4f ). As expected, siNT@ NPs or free siPol2 had no substantial effect on the cell proliferation. POLR2A expression is reduced in isogenic HCC1937 cell lines ( Fig. 4g , control groups and Supplementary Fig. 6c ). Furthermore, siPol2@NPs decrease POLR2A expression in all cells. Collectively, these data show that the materials in the nanoparticles (other than siPol2) do not have an effect on POLR2A expression in cells, nor their proliferation, and siPol2@NPs effectively kill POLR2A loss isogenic TNBC cells.
Suppressing PoLr2A inhibits POLR2A loss tumour growth
To establish orthotopic HCC1937 TNBC tumours, the isogenic POLR2A loss and wild-type POLR2A neutral HCC1937 cells were injected into the fourth inguinal mammary fat pad on the left and right sides of each mouse (Fig. 5a ). To examine the tumour targeting capability of the nanoparticles, siPol2 labelled with Cy5.5 was used to form Cy5.5-siPol2@NPs for in vivo imagining. As shown in Fig. 5a and Supplementary Fig. 7 , a highly enhanced fluorescence signal is observable in tumours at 8 h after administration of the Cy5.5-siPol2@NPs compared to free Cy5.5-siPol2, probably due to the enhanced permeability and retention effect of tumour vasculature 35, 44 . This observation was confirmed by ex vivo imaging of five major organs along with tumours harvested from the mice killed at 8 h ( Fig. 5b and Supplementary Fig. 7 ). On the one hand, only tumours from the Cy5.5-siPol2@NPs group present strong signal of Cy5.5, compared with tumours from the saline or free Cy5.5-siPol2 group. On the other hand, in the Cy5.5-siPol2@NPs group, the isogenic POLR2A loss tumours on the left have similar fluorescence intensity to the wild-type POLR2A neutral tumours on the right. This indicates that hemizygous loss of POLR2A does not affect the accumulation of nanoparticles in vivo, excluding the possibility that an enhanced therapeutic effect on the POLR2A loss tumour is due to improved agent accumulation in the tumours. No accumulation of the free or encapsulated Cy5.5-siPol2 is observable in heart or kidney. Weaker fluorescence is observable in livers from the free Cy5.5-siPol2 or Cy5.5-siPol2@NPs groups. This is expected because the agents are probably cleared out of the body through the liver.
To investigate material safety and antitumour efficacy, four different treatments (saline, free siPol2, siNT@NPs and siPol2@NPs) were applied twice a week after tumour establishment in nude mice (Fig. 5c ). Neither mouse death nor significant drop in body weight was observed in any groups during the experiments ( Supplementary  Fig. 8a ). No obvious damage was observable in the haematoxylin and eosin (H&E)-stained histology slices of five major organs collected from mice in the siPol2@NPs and saline groups ( Supplementary  Fig. 8b) . Moreover, no obvious changes in aspartate aminotransferase and alanine aminotransferase levels were observed in wild-type C57BL/6J mice with intact immune systems after being treated with the various formulations ( Supplementary Fig. 9 ), indicating that the nanoparticles are well tolerated by the animal. We also measured the serum level of tumour necrosis factor-α, interferon-γ, interleukin-6, interleukin-10 and monocyte chemoattractant protein-1 in the wild-type mice. Although significantly increased levels of interferon-γ and monocyte chemoattractant protein-1 were observed for the siNT@NP and siPol2@NP treatments at 6 h after injection, they returned to baseline levels on day 1 and thereafter. No significant difference was observed between the various conditions for all the other cytokines in 7 days, indicating negligible immune response induction by the nanoparticles.
Inhibiting POLR2A by siPol2@NPs significantly inhibited POLR2A loss tumour growth by ~80% (left panels in Fig. 5d-f ) compared with the tumour from the control (saline) group. By contrast, no significant antitumour effect was observed on the POLR2A neutral tumours (right panels in Fig. 5d-f ). As expected, the POLR2A protein levels in the siPol2@NPs treatment group were minimized ( Fig.  5g-i) . These data confirm that POLR2A silencing leads to selective suppression of POLR2A loss tumours. Moreover, histological staining revealed extensive necrosis in the POLR2A loss tumours only from the siPol2@NPs group (Fig. 5j) .
To confirm the findings with tumours derived from the isogenic pairs of HCC1937 cells, we used wild-type POLR2A loss (MDA-MB-453) and POLR2A neutral (MDA-MB-231) cells to establish orthotopic tumours and carried out treatment injections of saline, siNT@NPs and siPol2@NPs twice a week (Fig. 6a,b ). Neither mouse death nor significant body weight drop was observed in any group ( Supplementary Fig. 10a ), and no evident damage could be observed in all five organs from the siPol2@NPs treatment group ( Supplementary Fig. 10b ). Furthermore, siPol2@NPs exhibited excellent antitumour capacity to MDA-MB-453 (POLR2A loss ) tumours, while no significant difference in the growth of the MDA-MB-231 (POLR2A neutral ) tumours was observed in the three different groups (Fig. 6c-e ). The siPol2@NPs treatment minimized the POLR2A protein levels in the MDA-MB-453 tumours (Fig.  6f-h) , confirming that POLR2A silencing leads to tumour suppression in the POLR2A loss tumour model. Histological staining showed extensive necrosis in the POLR2A loss tumours only from the siPol2@ NPs group (Fig. 6l) .
It is worth noting that the strategy of targeting POLR2A using our siPol2@NPs can also be used to selectively inhibit the growth of POLR2A loss HER2+ HER18 breast cancer cells (in vitro) and tumours (in vivo) ( Supplementary Note 1 and Supplementary Figs. 11 and  12 ). Altogether, we show that the siPol2@NPs-based POLR2A suppression inhibits the growth of POLR2A loss MDA-MB-453 (TP53 −/ mut , POLR2A −/+ ), isogenic HCC1937 (TP53 mut/+ , POLR2A +/-) and isogenic HER18 (TP53 +/+ , POLR2A +/and TP53 +/-, POLR2A +/-) cells and tumours, regardless of their TP53 status. While TP53 and POLR2A are often co-deleted in a majority of human cancers with hemizygous loss of TP53, the status of TP53 has no significant impact on the anticancer activity of POLR2A inhibition.
Conclusions
In this study, by analysing TNBC databases, we have shown that the POLR2A gene is almost always co-deleted with TP53 in the Chr17p deletion region, and 53% of TNBC harbours this heterozygous deletion. Moreover, the POLR2A expression levels are highly correlated with the copy number of POLR2A, rendering cancer cells with heterozygous loss of TP53 vulnerable to POLR2A inhibition. This collateral loss of POLR2A with TP53 prompted us to use RNAi to precisely target POLR2A for TNBC treatment. To overcome the hurdles to cytosolic delivery of siRNA for RNAi, we developed a unique nanoplatform with a low-pH-activated bomb-like effect for endo/lysosomal escape. This improves cytosolic delivery of siPol2 to inhibit POLR2A in TP53 loss cells. The anticancer capability of siPol2@NPs in vivo was examined using three different orthotopic tumour models derived from both wild-type and isogenic cell lines.
The nanoparticles were found to preferentially accumulate in both the POLR2A neutral and POLR2A loss tumours. Importantly, our data show that, in tumours with heterozygous POLR2A loss, inhibition of POLR2A with siPol2-laden nanoparticles leads to enhanced reduction of the tumour growth with no evident systemic toxicity. This approach also possesses several important advantages for clinical applications (Supplementary Note 2). Collectively, this study may provide a promising nanotechnology-based precision-targeting strategy for fighting against TNBC and potentially many other types of cancer harbouring the common TP53 genomic alteration, regardless of the TP53 status.
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to show the location of siPol2. Uncropped scans of the gels are presented in Supplementary Fig. 13 .
Cell culture. MDA-MB-231, MDA-MB-453 and HCC1937 cell lines were purchased from the American Type Culture Collection (ATCC) and cultured under the standard conditions specified by ATCC. HER18 cells (which stably overexpress HER2) were a gift from M.-H. Lee (MD Anderson Cancer Centre). The cells were maintained in Dulbecco's modified eagle medium with 10% fetal bovine serum at 37 °C in 5% CO 2 . Cell identity was confirmed by validating the short tandem repeat (STR) DNA fingerprinting using the AmpFLSTR Identifiler Kit (Applied Biosystems) according to the manufacturer's instructions.
Generation of POLR2A-heterozygous cell lines. The generation of POLR2A loss isogenic cell lines was conducted using CRISPR-Cas9 as described previously 14 . Briefly, 2 × 10 6 of HCC1937 or HER18 cells were transfected with 2 μg of Cas9/ sgRNA-expressing vector DNA using a Nucleofector kit (Lonza). Genome editing efficacy was tested by the Surveyor assay. Single colonies were isolated and the PCR products from positive clones were ligated to the pGEM-T Easy Vector (Promega) and further confirmed by Sanger DNA sequencing.
Cellular uptake and intracellular distribution. The nanoparticles were encapsulated with Cy5.5-siPol2 using the aforementioned double-emulsion method. For nanoparticles without CO 2 , CG was used instead of CG-CO 2 . MDA-MB-453 cells were treated with the Cy5.5-siPol2@NPs at 37 °C for up to 6 h, then the cells were incubated at 37 °C for 30 min with 50 nM DAPI and 90 nM LysoTracker Green in cell culture medium. The cells were fixed with 4% paraformaldehyde and examined using a FluoView FV1000 confocal microscope from Olympus. For quantitative analysis of the co-localization between Cy5.5-siPol2 and LysoTracker Green inside cells, Manders' co-localization coefficients between the fluorescence signals of Cy5.5-siPol2 and LysoTracker Green were calculated using ImageJ (ImageJ bundled with 64-bit Java 1.8.0_112, https://imagej. nih.gov/ij) with the JACoP co-localization plugin module. The two Manders' coefficients M1 and M2 were calculated as follows:
where subscript i represents the ith pixel in the fluorescence image, R represents red fluorescence intensity, G represents green fluorescence intensity, T 1 represents the threshold for the red channel and T 2 represents the threshold for the green channel. The two fluorescence intensities and thresholds were determined by the built-in algorithm of the JACoP co-localization plugin module of ImageJ for both the green and red channels.
Immunoblotting. Immunoblotting was performed as described previously 14 .
Briefly, cell lysates were made in lysis buffer (pH 7.5) containing 1 mM EDTA, 50 mM Tris, 150 mM NaCl, 0.5% Triton X-100, 0.5% NP-40, 1 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, 5 mM sodium vanadate and 1 μg ml −1 leupeptin, aprotinin and pepstatin. Proteins were then separated by SDS-PAGE gels and further transferred to the membranes of polyvinylidene difluoride (Bio-Rad). After blocking the membranes with 5% non-fat milk for 1 h at room temperature, they were incubated with primary antibodies as indicated. The membranes were washed and incubated at room temperature with peroxidaseconjugated secondary antibodies for 1 h. After washing five times, immunodetected bands on the membranes were visualized by taking chemiluminescent images on X-ray films with an enhanced chemiluminescence system (PerkinElmer) according to the manufacturer's instructions. All uncropped scans are shown in Supplementary Fig. 13 for the western blots.
Cell viability and cell colony formation assays. Equal numbers of cells were plated in 96-well plates in triplicate. After incubation with indicated treatments for 72 h, cell viability was quantified using the CCK-8 kit according to the manufacturer's instructions. For the cell colony formation assay, cell colonies were
Methods
The Cancer Genome Atlas analysis. The Cancer Genome Atlas primary (origin: METABRIC Nature 2012 45 and Nature Communications 2016 46 , and Cell 2015 47 ) and metastatic (origin: France 2016) breast cancer data were downloaded from cBioPortal (http://atlasgeneticsoncology.org/tcga_projects.html), including copy number variation at the segment level in log-ratio, copy number variation at gene levels estimated using the GISTIC2 algorithm, RNA-seq for gene expression in the base-2 log scale and patient information on oestrogen receptor, progesterone receptor and HER-2/neu status. We analysed the correlation between gene copy number and the corresponding gene expression as previously described 14 . The TNBC subtypes, defined by PAM50 profiling tests, included all the basal-like and claudin-low groups.
Materials. PLGA (lactide:glycolide, 75:25; M w = 4,000-15,000 Da) and organic solvents were purchased from Sigma. Agarose, ethidium bromide and loading buffer were purchased from Thermo Fisher Scientific, DPPC was purchased from Anatrace, chitosan oligosaccharide of pharmaceutical grade (M w = 1.2 kDa, 95% deacetylation) was purchased from Zhejiang Golden Schell Biochemical Co. and methyl aminomethanimidothioate hydroiodide was purchased from Santa Cruz Biotechnology. Anti-POLR2A antibody (sc-47701, dilution of 1:10,000 for western blot and 1:200 for immunofluorescence staining), horseradish peroxidase (HRP)anti-rabbit IgG (sc-2030, dilution of 1:5,000), HRP-anti-mouse IgG (sc-516102, dilution of 1:5,000) antibodies were purchased from Santa Cruz. Anti-β-actin (AM1829B, dilution of 1:5,000) antibody was purchased from Abgent. Alexa Fluor 488-labelled anti-mouse IgG (A11001, dilution of 1:250) antibody was purchased from Life Technologies. The CCK-8 kit was purchased from Dojindo Molecular Technologies, the mouse inflammation kit (#552364) was purchased from BD Biosciences, and the alanine transaminase (ALT) activity assay kit (ab105134) and aspartate aminotransferase (AST) activity assay kit (ab105135) were purchased from Abcam.
Nanoparticle synthesis. The double-emulsion method 48 , with slight modification, was used to synthesize the nanoparticles used in this study. Chitosanguanidinate was synthesized by modifying chitosan with the guanidine group (Fig. 2b) , a common functional group in many natural products, including the naturally occurring amino acid l-arginine. Briefly, 480 mg of chitosan (1 kDa) was dissolved in 12 ml of deionized (DI) water. A 6-ml volume of methyl aminomethanimidothioate hydroiodide in acetonitrile (145 mg ml −1 ) was then added and stirred at room temperature for 24 h under a N 2 atmosphere, and the solvent and side product were removed under vacuum. Finally, to remove the unreacted methyl aminomethanimidothioate hydroiodide, the solid was dissolved in 1 ml of DI water and dropped into 10 ml of tetrahydrofuran (THF), filtered, and the final solid CG collected for further use. To capture CO 2 , CG-CO 2 was made by bubbling the aqueous solution of CG for 1 h with CO 2 . To synthesize nanoparticles, 10 mg of DPPC and 20 mg of PLGA were dissolved in dichloromethane (DCM, 2 ml). This organic solution and 400 µl of DI water dissolved with 1 mg ml −1 CG-CO 2 and 500 µg ml −1 POLR2A siRNA (without or with Cy5.5 modification, Sigma) were transferred into a centrifuge tube (50 ml). The sample was then emulsified for 1 min by sonication with a Branson 450 sonifier at 18% power. A total of 8 ml of poly(vinyl alcohol) (PVA) solution (2% in DI water) was added into the centrifuge tube and the sample was further emulsified, as before, for 1 min. The organic solvent (DCM) was removed by rotary evaporation. The nanoparticles were then collected by centrifugation for 10 min at 10,000g and washed twice in DI water at room temperature.
Nanoparticle characterization. Both dynamic light scattering (DLS) and TEM were used to characterize the nanoparticles. The nanoparticles were soaked for 6 h in either acetate buffer (pH 5.0) or phosphate buffer (pH 6.0 and 7.4). For TEM studies, uranyl acetate solution (2%, wt/wt) was used to negatively stain the nanoparticles before examining them with a Tecnai G2 Spirit transmission electron microscope from FEI. The size distribution of the nanoparticles was studied using a 90 Plus/BI-MAS DLS instrument from Brookhaven. The encapsulation efficiency of the siRNA was 68.6 ± 7.2%, which was calculated as the ratio of the amount of siRNA encapsulated in the nanoparticles to the total amount of siRNA fed for encapsulation. The loading content of the siRNA in the nanoparticles was 0.73 ± 0.25%, which was calculated as the ratio of the amount of siRNA encapsulated in the nanoparticles to the total amount of nanoparticles including the siRNA. Both the encapsulation efficiency and loading content were quantified by using Cy5.5-siPol2 for encapsulation. The amount of Cy5.5-siPol2 in a sample was measured spectrophotometrically using a Beckman Coulter DU 800 UV-vis spectrophotometer based on its absorbance peak at 670 nm. A standard curve for free Cy5.5-siPol2 (absorbance versus concentration) was used to convert the measured absorbance into the concentration of Cy5.5-siPol2 in a sample.
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